Although animal pharmaceutical companies have an intrinsic role in driving the risk of AMR, we continue to see a lack of scrutiny over these companies and their practices. There is a clear need for greater disclosure and transparency over how companies are producing, selling and marketing antibiotics, as well as a need to strengthen standards and policies across the industry to mitigate the risk of AMR. Forward-looking companies with exposure to antibiotics will need to pre-empt changes that could restrict their market access and erode consumer trust in their brands and sectors. However, diversifying into alternatives, such as diagnostic tools, vaccines, nutritional supplements and novel treatments, is a step towards limiting these risks.

Target companies:

• Zoetis
• Elanco
• MSD
• Phibro
• Virbac
• Dechra
• Vetoquinol